Updated:
ImmunityBio (formerly NantKwest)
ImmunityBio is a commercial-stage biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to...
ImmunityBio (formerly NantKwest)
ImmunityBio is a commercial-stage biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems. At the core of its strategy is the Cancer BioShield platform, anchored by the IL-15 superagonist ANKTIVA.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Culver City
Corporate office
Culver City, CA, United States
Additional offices
Chicago · San Ramon · San Diego
Principals
Dr. Patrick Soon-Shiong
Founder, Executive Chairman and Global Chief Scientific and Medical Officer
Richard Adcock
President and Chief Executive Officer
Dr. Jim Yong Kim
Vice Chairman
Hemanth Ramaprakash
PhD, MBA, Investors contact
Sarah Singleton
Media contact
Sector focus
Frequently asked questions
What is ANKTIVA and how does it work?
ANKTIVA is an FDA-approved immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease. It is administered intravesically and activates NK cells, T cells, and macrophages to attack cancer cells while preserving the immune system. The therapy is now marketed in the U.S. and Saudi Arabia.
Does ImmunityBio engage in fund commitments or direct investments?
No. ImmunityBio is a development-stage biopharmaceutical company focused on R&D, clinical trials, and commercialization of its own therapeutics. It does not participate in fund commitments or direct external investments. Its financial activities relate to corporate financing, such as non-dilutive debt and equity offerings.
How does ImmunityBio source its proprietary technology?
ImmunityBio's technology is developed internally via its research team and through partnerships. The company's platform is built on activating multiple immune pathways, including NK cells and T cells, using proprietary constructs and adjuvants. Its science is disclosed in SEC filings and academic presentations.
What investment stages does ImmunityBio target?
ImmunityBio does not invest; it is a biotech company targeting later-stage clinical development (Phase 2 and Phase 3 trials) and commercialization. Its pipeline includes both early and late-stage programs in bladder cancer, lung cancer, and infectious diseases.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: